Physician profile
Randeep Suneja
NPI 1225198377
$25,550.39
in general payments reported to CMS, 2019-2025
48 companies · $1,555 in 2025
The $1,555 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,521 · 2020: $7,998 · 2021: $8,993 · 2022: $1,696 · 2023: $2,844 · 2024: $943 · 2025: $1,555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,979 · Consulting Fee: $1,363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,979.19 |
| Consulting Fee | $1,362.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $7,777.16 | 2019-2024 | Farxiga, Brilinta |
| Esperion Therapeutics, INC. | $7,414.63 | 2020-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $2,103.05 | 2019-2025 | Leqvio |
| Janssen Pharmaceuticals, INC | $927.42 | 2019-2022 | |
| Amgen INC. | $735.77 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $586.54 | 2021-2025 | Verquvo, Capvaxive |
| Boston Scientific Corporation | $585.77 | 2019-2025 | Comet, Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Abbott Laboratories | $569.09 | 2019-2025 | Cardiomems |
| Amarin Pharma, INC. | $447.32 | 2019-2022 | |
| Pfizer INC. | $364.82 | 2020-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $347.56 | 2019-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $298.07 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $292.50 | 2020-2025 | Camzyos, Eliquis |
| Heartflow, INC. | $282.15 | 2019-2025 | Ffrct |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.86 | 2019-2025 | Jardiance |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $270.01 | 2021-2025 | |
| Cleerly, INC. | $243.51 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Kowa Pharmaceuticals America, INC. | $176.28 | 2020-2023 | Livalo |
| Altathera Pharmaceuticals LLC | $176.02 | 2022-2024 | Sotalol Hydrochloride |
| Althera Pharmaceuticals LLC | $170.80 | 2021-2022 | |
| Scpharmaceuticals INC. | $155.30 | 2023-2025 | |
| Madrigal Pharmaceuticals | $148.77 | 2025 | Rezdiffra |
| Medtronic, INC. | $131.74 | 2021-2025 | Linq II |
| Novo Nordisk INC | $101.81 | 2022-2025 | Ozempic, Rybelsus |
| Arbor Pharmaceuticals, INC. | $88.12 | 2019-2022 | |
| Cvrx, INC. | $85.95 | 2022-2023 | Barostim Neo System |
| Astellas Pharma US INC | $82.12 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $70.65 | 2019 | |
| Impulse Dynamics (USA) INC. | $61.90 | 2023-2024 | Optimizer, Optimizer |
| Edwards Lifesciences Corporation | $56.21 | 2022-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Actelion Pharmaceuticals US, INC. | $45.46 | 2025 | Opsumit, Uptravi |
| Lexicon Pharmaceuticals, INC. | $43.46 | 2023 | Inpefa |
| Azurity Pharmaceuticals, INC. | $40.93 | 2025 | Edarbi |
| Preventice Services, LLC | $39.12 | 2020-2021 | |
| Bridgebio Pharma, INC. | $37.19 | 2025 | Attruby |
| Lundbeck LLC | $37.07 | 2020 | |
| Irhythm Technologies, INC. | $35.54 | 2023-2024 | Zio Xt Patch |
| Medtronic Vascular, INC. | $33.12 | 2019-2020 | |
| Kiniksa Pharmaceuticals, Ltd. | $32.91 | 2021-2023 | Arcalyst |
| Chiesi USA, INC. | $32.67 | 2021 | |
| Agepha Pharma Fz LLC | $31.14 | 2024-2025 | Lodoco |
| Dexcom, INC. | $24.73 | 2025 | Dexcom G6 Transmitter |
| Eisai INC. | $22.04 | 2025 | |
| Philips North America LLC | $19.95 | 2020 | |
| Inspire Medical Systems, INC. | $19.81 | 2025 | Inspire |
| Bardy Diagnostics, INC. | $16.49 | 2020 | |
| Atricure, INC. | $13.86 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randeep Suneja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.